bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association Read more about bluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association
bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting Read more about bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
bluebird bio to Present at Investor Conferences in May Read more about bluebird bio to Present at Investor Conferences in May
Deutsche Bank 43rd Annual Healthcare Conference Read more about Deutsche Bank 43rd Annual Healthcare Conference
Bank of America Merrill Lynch 2018 Healthcare Conference Read more about Bank of America Merrill Lynch 2018 Healthcare Conference
bluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress
bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia Read more about bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day Read more about Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day
bluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day Read more about bluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States Read more about bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States